Adalimumab

Subcutaneous TNF inhibitors and their biosimilars are discontinued due to inefficacy and adverse events at similar rates in patients with rheumatic diseases, according to data from Spain published in The Journal of Rheumatology.

In patients with rheumatoid arthritis who have an inadequate response to methotrexate, a treatment sequence beginning with a biosimilar appeared cost-effective compared with leflunomide, according to data published in JAMA Network Open.

In this edition, extensive psoriasis and IBD history predict difficult-to-treat psoriatic arthritis, targeted therapies demonstrate low risk for serious infection and more.

Serious infections were uncommon among patients with psoriatic arthritis exposed to targeted therapies for the first time in “a large and exhaustive” French cohort, according to data published in RMD Open.

In this video, Maria Danila, MD, discusses recent advancements in rheumatoid arthritis.

Although TNF inhibitors remain the first choice biologic for many rheumatologists treating psoriatic arthritis, interleukin-17 inhibitors may soon overtake them, according to a market analysis from Spherix Global Insights.

Approximately two-thirds of patients with Crohn’s disease who initially responded to anti-tumor necrosis factor therapy lost response by 3 years, with researchers suggesting that higher drug concentrations at induction may improve outcomes.

Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights.

In this Healio video exclusive, Leonard Calabrese, DO, chief medical editor of Healio Rheumatology, discussed the top items from the February issue, including an exploration of how the placebo effect can be applied in rheumatology.

The FDA has approved Simlandi as the third interchangeable biosimilar to Humira following a rejection in April 2023 stemming from issues at the developer’s manufacturing facility.